For the twelve months ended Sep 30, 2026, Monte Rosa Therapeutics Inc. reported $70.33M of revenue and -$130.97M of net income.
GLUE revenue was $54.37M in fiscal Q3 2026 (ended Sep 30, 2026), up 325.8% from a year earlier and up 506.2% from the prior quarter. For the full fiscal 2025 it was $123.67M, up 63.5% from fiscal 2024.
GLUE net income was $3.06M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$27.08M a year earlier. For the full fiscal 2025 it was -$38.63M, compared with -$72.70M in fiscal 2024.
GLUE diluted EPS was $0.03 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.33 a year earlier. For the full fiscal 2025 it was -$0.46, compared with -$0.98 in fiscal 2024.
GLUE free cash flow was -$42.54M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $99.78M a year earlier. For the full fiscal 2025 it was -$27.50M, compared with $38.01M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $123.67M | $75.62M | $0 | - | - | - |
| Research and development | $141.50M | $121.56M | $111.27M | $85.06M | $57.16M | $24.00M |
| Selling, general and admin | $36.38M | $35.17M | $32.04M | $27.32M | $15.73M | $4.00M |
| Operating income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M | -$28.01M |
| Pre-tax income | -$39.72M | -$70.13M | -$135.01M | -$108.50M | - | - |
| Income tax | -$1.10M | $2.57M | $338.0K | $0 | - | - |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | -$73.96M | -$35.88M |
| EPS, basic | -$0.46 | -$0.98 | -$2.63 | -$2.30 | -$2.96 | -$23.65 |
| EPS, diluted | -$0.46 | -$0.98 | -$2.63 | -$2.30 | -$2.96 | -$23.65 |
| Diluted shares | 83.1M | 73.9M | 51.4M | 47.2M | 25.0M | 1.5M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $129.88M | $229.12M | $132.68M | $60.19M | $351.41M | $42.86M |
| Current assets | $393.19M | $377.44M | $236.21M | $275.89M | $348.67M | $43.59M |
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M |
| Current liabilities | $64.21M | $156.95M | $46.59M | $25.57M | $16.64M | $29.27M |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M | $30.34M |
| Shareholders' equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M | -$48.73M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -$59.36M | -$23.05M |
| Capital expenditures | $4.70M | $3.99M | $19.04M | $12.91M | $9.73M | $3.39M |
| Free cash flow | -$27.50M | $38.01M | -$62.84M | -$105.38M | -$69.09M | -$26.44M |
| Investing cash flow | -$101.83M | -$44.45M | $88.80M | -$219.22M | -$9.65M | -$3.39M |
| Financing cash flow | $30.35M | $98.89M | $27.49M | $20.47M | $377.56M | $60.06M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | - |
| Stock-based compensation | $18.86M | $18.13M | $16.67M | $11.66M | $5.20M | $354.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 63.5% | - | - | - | - | - |
| Operating margin | -43.8% | -107.3% | - | - | - | - |
| Net margin | -31.2% | -96.1% | - | - | - | - |
| Free cash flow margin | -22.2% | 50.3% | - | - | - | - |
| Return on equity | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% | - |
| Return on assets | -8.6% | -16.6% | -44.6% | -31.7% | -20.2% | -72.7% |
| Current ratio | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 | 1.49 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.37M | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | $84.93M | $60.65M | $9.22M | $4.70M | $1.06M | $0 |
| Research and development | $45.36M | $47.96M | $44.07M | $41.98M | $36.68M | $30.65M | $32.19M | $38.87M | $27.62M | $28.05M | $27.03M | $27.14M |
| Selling, general and admin | $10.94M | $10.13M | $10.18M | $10.52M | $9.06M | $8.10M | $8.70M | $8.78M | $8.13M | $9.28M | $8.98M | $7.73M |
| Operating income | -$1.94M | -$49.13M | -$50.03M | -$49.72M | -$32.98M | -$15.55M | $44.04M | $13.00M | -$26.53M | -$32.64M | -$34.95M | -$34.86M |
| Pre-tax income | $3.78M | -$43.19M | -$44.45M | -$46.08M | -$30.26M | -$11.10M | $47.71M | $15.60M | -$23.79M | -$30.06M | -$31.89M | -$33.27M |
| Income tax | $716.0K | $208.0K | $52.0K | $59.0K | -$3.18M | $1.20M | $822.0K | $2.16M | $71.0K | $252.0K | $83.0K | -$22.0K |
| Net income | $3.06M | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | $46.88M | $13.44M | -$23.86M | -$30.31M | -$31.97M | -$33.25M |
| EPS, basic | $0.03 | -$0.43 | -$0.45 | -$0.55 | -$0.33 | -$0.15 | $0.57 | - | -$0.29 | -$0.43 | -$0.53 | -$0.57 |
| EPS, diluted | $0.03 | -$0.43 | -$0.45 | -$0.55 | -$0.33 | -$0.15 | $0.57 | - | -$0.29 | -$0.43 | -$0.53 | -$0.57 |
| Diluted shares | 108.6M | 101.5M | 99.9M | - | 82.4M | 82.2M | 83.0M | - | 82.0M | 71.2M | 60.2M | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.18M | $90.10M | $159.86M | $129.88M | $208.34M | $69.43M | $78.53M | $229.12M | $125.58M | $108.85M | $99.75M | $132.68M |
| Receivables | - | - | - | - | - | - | - | - | - | $9.00M | - | - |
| Current assets | $640.07M | $631.41M | $677.55M | $393.19M | $401.82M | $299.46M | $332.28M | $377.44M | $251.21M | $277.90M | $199.04M | $236.21M |
| Total assets | $697.73M | $691.16M | $736.43M | $448.66M | $459.84M | $359.59M | $393.20M | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M |
| Current liabilities | $62.05M | $59.66M | $71.04M | $64.21M | $61.44M | $41.85M | $59.22M | $156.95M | $41.64M | $42.35M | $41.29M | $46.59M |
| Total liabilities | $201.52M | $203.88M | $214.51M | $215.60M | $214.00M | $91.51M | $118.04M | $215.80M | $109.62M | $119.44M | $114.23M | $124.50M |
| Shareholders' equity | $496.21M | $487.28M | $521.92M | $233.06M | $245.84M | $268.08M | $275.16M | $222.94M | $205.46M | $224.67M | $152.52M | $179.25M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.98M | -$44.11M | -$37.37M | -$43.01M | $100.43M | -$34.72M | -$45.49M | $128.92M | -$20.99M | -$27.77M | -$38.16M | $29.63M |
| Capital expenditures | $1.56M | $4.72M | $1.87M | $767.0K | $651.0K | $1.70M | $1.59M | $183.0K | $399.0K | $2.02M | $1.38M | $1.69M |
| Free cash flow | -$42.54M | -$48.84M | -$39.24M | -$43.78M | $99.78M | -$36.41M | -$47.08M | $128.74M | -$21.39M | -$29.79M | -$39.55M | $27.95M |
| Investing cash flow | -$4.54M | -$28.86M | -$261.00M | -$65.07M | $38.14M | $25.32M | -$100.23M | -$30.90M | $37.75M | -$61.16M | $9.85M | $14.30M |
| Financing cash flow | $568.0K | $3.21M | $328.33M | $29.62M | $348.0K | $365.0K | $14.0K | $608.0K | $15.0K | $98.02M | $246.0K | $25.17M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-based compensation | $6.32M | $5.97M | $5.95M | $4.31M | $4.36M | $4.89M | $5.30M | $4.47M | $4.28M | $4.50M | $4.87M | $4.07M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 325.8% | -61.3% | -95.0% | -95.4% | 38.5% | 394.0% | 7882.0% | - | - | - | - | - |
| Operating margin | -3.6% | -547.8% | -1188.5% | -1787.7% | -258.3% | -67.1% | 51.9% | 21.4% | -287.8% | -695.3% | -3284.5% | - |
| Net margin | 5.6% | -483.9% | -1057.1% | -1658.9% | -212.1% | -53.0% | 55.2% | 22.2% | -258.9% | -645.6% | -3004.5% | - |
| Free cash flow margin | -78.2% | -544.6% | -932.0% | -1574.3% | 781.5% | -157.0% | -55.4% | 212.3% | -232.1% | -634.5% | -3717.0% | - |
| Current ratio | 10.32 | 10.58 | 9.54 | 6.12 | 6.54 | 7.16 | 5.61 | 2.40 | 6.03 | 6.56 | 4.82 | 5.07 |
Source: XBRL data Monte Rosa Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GLUE | $70.33M | -61.3% | -$130.97M | -186.2% | $904.1M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |